Evidence map›Paper›PMID 32879760›Full record

Observational studyTranslational vision science & technology2020

Tear Proteomic Predictive Biomarker Model for Ocular Graft Versus Host Disease Classification.

Olivia E O'Leary, Andreas Schoetzau, Ludovic Amruthalingam, Nadine Geber-Hollbach, Kim Plattner, Paul Jenoe, Alexander Schmidt, Christoph Ullmer, Faye M Drawnel, Sascha Fauser and 4 more

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Translational vision science & technology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Applications of artificial intelligence and bioinformatics methodologies in the analysis of ocular biofluid markers: a scoping review.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2024
    Article
  7. Review
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Olivia E O'LearyDepartment of Ophthalmology, University Hospital Basel, University of Basel, Basel, Switzerland.
Andreas SchoetzauDepartment of Ophthalmology, University Hospital Basel, University of Basel, Basel, Switzerland.
Ludovic AmruthalingamDepartment of Biomedical Engineering, University of Basel, Basel, Switzerland.
Nadine Geber-HollbachDepartment of Ophthalmology, University Hospital Basel, University of Basel, Basel, Switzerland.
Kim PlattnerDepartment of Ophthalmology, University Hospital Basel, University of Basel, Basel, Switzerland.
Paul JenoeProteomics Core Facility, Biozentrum, University of Basel, Basel, Switzerland.
Alexander SchmidtProteomics Core Facility, Biozentrum, University of Basel, Basel, Switzerland.
Christoph UllmerPharma Research and Early Development, Roche Innovation Center, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Faye M DrawnelPharma Research and Early Development, Roche Innovation Center, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Sascha FauserPharma Research and Early Development, Roche Innovation Center, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Hendrik P N SchollDepartment of Ophthalmology, University Hospital Basel, University of Basel, Basel, Switzerland.
Jakob PasswegDepartment of Hematology, University Hospital Basel, University of Basel, Basel, Switzerland.
Joerg P HalterDepartment of Hematology, University Hospital Basel, University of Basel, Basel, Switzerland.
David GoldblumDepartment of Ophthalmology, University Hospital Basel, University of Basel, Basel, Switzerland.
University of Basel · CHRoche (Switzerland) · CHUniversity Hospital of Basel · CHJohns Hopkins University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Diagnosis of ocular graft-versus-host disease (oGVHD) is hampered by a lack of clinically-validated biomarkers. This study aims to predict disease severity on the basis of tear protein expression in mild oGVHD. Methods: Forty-nine patients with and without chronic oGVHD after AHCT were recruited to a cross-sectional observational study. Patients were stratified using NIH guidelines for oGVHD severity: NIH 0 (none; n = 14), NIH 1 (mild; n = 9), NIH 2 (moderate; n = 16), and NIH 3 (severe; n = 10). The proteomic profile of tears was analyzed using liquid chromatography-tandem mass spectrometry. Random forest and penalized logistic regression were used to generate classification and prediction models to stratify patients according to disease severity. Results: Mass spectrometry detected 785 proteins across all samples. A random forest model used to classify patients by disease grade achieved F1-measure values for correct classification of 0.95 (NIH 0), 0.8 (NIH 1), 0.74 (NIH 2), and 0.83 (NIH 3). A penalized logistic regression model was generated by comparing patients without oGVHD and those with mild oGVHD and applied to identify potential biomarkers present early in disease. A panel of 13 discriminant markers achieved significant diagnostic accuracy in identifying patients with moderate-to-severe disease. Conclusions: Our work demonstrates the utility of tear protein biomarkers in classifying oGVHD severity and adds further evidence indicating ocular surface inflammation as a main driver of oGVHD clinical phenotype. Translational Relevance: Expression levels of a 13-marker tear protein panel in AHCT patients with mild oGVHD may predict development of more severe oGVHD clinical phenotypes.

Indexed as

Graft vs Host DiseaseBiomarkersCross-Sectional StudiesHumansProteomicsTearsBiomarkersbiomarkersmass spectrometryocular graft versus host diseaseseverity classificationtear proteins

Identifiers

PMID32879760
PMCPMC7442883
OpenAlexW3047382874

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.